These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21527455)

  • 1. Angiotensin receptor blockers and cardiovascular outcomes.
    Hobbs FD
    BMJ; 2011 Apr; 342():d2193. PubMed ID: 21527455
    [No Abstract]   [Full Text] [Related]  

  • 2. Fraudulent data: an apology and the fate of angiotensin receptor blockers.
    Bangalore S; Messerli FH
    BMJ; 2013 Sep; 347():f5549. PubMed ID: 24048298
    [No Abstract]   [Full Text] [Related]  

  • 3. Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer.
    Volpe M; Azizi M; Danser AH; Nguyen G; Ruilope LM
    Eur Heart J; 2011 Jan; 32(1):19-22. PubMed ID: 20965885
    [No Abstract]   [Full Text] [Related]  

  • 4. [Angiotensin receptor blockers and risk of cancer].
    Zoghi M
    Anadolu Kardiyol Derg; 2011 Jun; 11(4):374-5. PubMed ID: 21592932
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction.
    Messerli FH; Bangalore S
    Circulation; 2017 May; 135(22):2085-2087. PubMed ID: 28559492
    [No Abstract]   [Full Text] [Related]  

  • 7. The "ARB-MI paradox": real or a fluke?
    Graber MA; Dachs R; Darby-Stewart A
    Am Fam Physician; 2012 Jul; 86(2):136-41. PubMed ID: 22962926
    [No Abstract]   [Full Text] [Related]  

  • 8. [Do angiotensin receptor blockers increased the risk of myocardial infarction? The landscape after ONTARGET study].
    Grajek S
    Kardiol Pol; 2008 Dec; 66(12):1313-24. PubMed ID: 19169980
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema.
    Beavers CJ; Dunn SP; Macaulay TE
    Ann Pharmacother; 2011 Apr; 45(4):520-4. PubMed ID: 21427294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of angiotensin receptor blockers in diabetic nephropathy.
    Sharma AM; Weir MR
    Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARBs and Myocardial Infarction.
    Med Lett Drugs Ther; 2005 May; 47(1208):38-9. PubMed ID: 15880086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do angiotensin II receptor blockers increase the risk of myocardial infarction?
    Verdecchia P; Angeli F; Gattobigio R; Reboldi GP
    Eur Heart J; 2005 Nov; 26(22):2381-6. PubMed ID: 16081468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes.
    Lewis EJ;
    BMJ; 2005 May; 330(7502):1269-70; author reply 1270-1. PubMed ID: 15920133
    [No Abstract]   [Full Text] [Related]  

  • 15. Angiotensin receptor blockers and cancer - Relationship dismissed by VALUE data while waiting for EMA and FDA reports.
    Kjeldsen SE; Hedner T; Oparil S; Narkiewicz K
    Blood Press; 2010 Oct; 19(5):271-2. PubMed ID: 20858047
    [No Abstract]   [Full Text] [Related]  

  • 16. [The effect of ARB on prevention of atherosclerosis].
    Aoyama T; Minatoguchi S
    Nihon Rinsho; 2011 Jan; 69(1):92-9. PubMed ID: 21226267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk, drugs and erectile function--a systematic analysis.
    Baumhäkel M; Schlimmer N; Kratz M; Hackett G; Jackson G; Böhm M
    Int J Clin Pract; 2011 Mar; 65(3):289-98. PubMed ID: 21314866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
    Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors and angiotensin receptor blockers: should they be stopped or not before ambulatory anaesthesia?
    Smith I; Jackson I
    Curr Opin Anaesthesiol; 2010 Dec; 23(6):687-90. PubMed ID: 20805745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
    Walfisch A; Al-maawali A; Moretti ME; Nickel C; Koren G
    J Obstet Gynaecol; 2011 Aug; 31(6):465-72. PubMed ID: 21823839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.